Raquel Calle Calle

Raquel Calle Calle

Auto-generated profile, based on publicly available information

Raquel Calle Calle

Servicio de Neurología, Hospital Universitario Virgen de las Nieves, Granada, España

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Neurología
Verified
Journal Article
Open access
CCC. Carnero-Pardo
C. Carnero-Pardo
IRI. Rego-García
I. Rego-García
JBJosé María Barrios-López
José María Barrios-López
SBS. Blanco-Madera
S. Blanco-Madera
RCR. Calle-Calle
R. Calle-Calle
RVR.M. Vílchez-Carrillo
R.M. Vílchez-Carrillo
The Mini-Cog is a very brief, widely used cognitive test that includes a memory task and a simplified assessment of the Clock Drawing Test (CDT). There is not a formal evaluation of the Mini-Cog test in Spanish. This study aims to analyse the diagnostic usefulness of the Mini-Cog and CDT for detecting cognitive impairment (CI). We performed a cross-sectional study, systematically including all patients who consulted at our neurology clinic over a 6-month period. We assessed diagnostic usefulness for detecting CI (defined according to the National Institute on Aging-Alzheimer's Association criteria for mild cognitive impairment and dementia) according to the area under the receiver operating characteristic curve (AUC). Sensitivity, specificity, and positive and negative likelihood ratios were calculated for each cut-off point. The study included 581 individuals (315 with CI); 55.1% were women and 27.7% had not completed primary studies. The Mini-Cog showed greater diagnostic usefulness than the CDT (AUC±sensitivity: 0.88±0.01 vs 0.84±0.01; P<.01). Both instruments were less useful for screening in individuals with a low education level (0.74±0.05 vs 0.75±0.05, respectively). A cut-off point of 2/3 in the Mini-Cog achieved a sensitivity of 0.90 (95%CI, 0.87-0.93) and a specificity of 0.71 (95%CI, 0.65-0.76); a cut-off point of 5/6 in the CDT achieved a sensitivity of 0.77 (95%CI, 0.72-0.81) and a specificity of 0.80 (95%CI, 0.75-0.85). In our neurology clinic, the Mini-Cog showed acceptable diagnostic usefulness for detecting CI, greater than that of the CDT; neither test is an appropriate instrument for individuals with a low level of education.

1 April 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
CRCalle-Calle Raquel
Calle-Calle Raquel
TLTriguero-Cueva Lucía
Triguero-Cueva Lucía
VCValderrama-Martín Carmen
Valderrama-Martín Carmen
RARomero-Villarrubia Ana
Romero-Villarrubia Ana
TATapia-Gómez Antonio
Tapia-Gómez Antonio
ACArnal-García Carmen
Arnal-García Carmen

27 March 2026 in Epileptic Disorders
Verified
Journal Article
Open access
ÁBÁlvaro Sánchez‐Guijo Benavente
Álvaro Sánchez‐Guijo Benavente
GMGuillermina García Martín
Guillermina García Martín
EREstuardo Daniel Castro Ruiz
Estuardo Daniel Castro Ruiz
Pablo Cabezudo-GarcíaPablo Cabezudo-García
Pablo Cabezudo-García
YMYolanda López Moreno
Yolanda López Moreno
Pedro Jesús Serrano-CastroPedro Jesús Serrano-Castro
Pedro Jesús Serrano-Castro
Objective: Patients with drug‐resistant epilepsy (DRE) typically take multiple anti‐seizure medications (ASMs) and are at risk of treatment‐related adverse events (AEs). This study assessed the impact of cenobamate monotherapy or dual therapy in patients with drug‐resistant epilepsy. Methods: This was a multicenter (six Spanish epilepsy units), retrospective, observational study in patients with drug‐resistant epilepsy who had received treatment with cenobamate as monotherapy (after conversion from polytherapy) or in dual therapy for at least three consecutive months, between April 2017 and November 2024. Results: In total, 125 patients (mean age 46 ± 15.9 years; median epilepsy duration 16 years, range: 1–65) were included. Median follow‐up was 11 months (range 3–80). Patients had received a median of 5 (range 2–19) previous anti‐seizure medications and were receiving a median of 2 (range 0–3) concomitant anti‐seizure medications at cenobamate initiation; the most common concomitant anti‐seizure medications were lacosamide (36%), brivaracetam (29.6%), and clobazam (26.4%). The median cenobamate dose at the last visit was 200 mg/day (range 100–400 mg/day). By the last visit, 31.5% of patients had achieved seizure freedom, and 75.8%, 58.1%, and 49.2% had achieved ≥50%, ≥75%, and ≥90% reductions in seizure frequency, respectively. During cenobamate treatment, 52% of patients discontinued one, 32% discontinued two, and 4% discontinued three concomitant anti‐seizure medications. In total, 63/125 patients (50.4%) had adverse events during cenobamate treatment, all mild or moderate; 40.8% of patients had adverse events at the last visit. The most reported adverse events were somnolence (22.4%), dizziness (10.4%), fatigue (7.2%), and instability (4.8%). Significance: This study highlights the real‐world effectiveness and safety of cenobamate, either as monotherapy (after conversion from polytherapy) or in dual therapy, in patients with drug‐resistant epilepsy. Cenobamate allows for a significant treatment simplification, resulting in fewer treatment‐related adverse events without compromising seizure reduction.

1 October 2020 in Neurología
Verified
Journal Article
Open access
RCR. Calle Calle
R. Calle Calle
LCL. Triguero Cueva
L. Triguero Cueva
AMA. Espigares Molero
A. Espigares Molero
JMJ.F. Maestre Moreno
J.F. Maestre Moreno